Evidence map›Paper›PMID 42323493›Full record

ArticleEuropean journal of human genetics : EJHG2026

Transcriptome-wide association studies implicate RCC1 and PHACTR4 in prostate cancer survival.

Weijia Fu, Joseph H Rothstein, Olle Melander, Hans Lilja, Weiva Sieh, Xiaoyu Song, Robert J Klein

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Weijia FuTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Joseph H RothsteinDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Olle MelanderDepartment of Clinical Sciences, Lund University, Malmö, Sweden.
Hans LiljaDepartments of Pathology and Laboratory Medicine, Surgery (Urology Service), and Medicine (GU-Oncology Service), Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-5871-7846
Weiva SiehDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-0085-1190
Xiaoyu SongTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. song.xiaoyu@duke-nus.edu.sg.ORCID http://orcid.org/0000-0003-1909-6244
Robert J KleinTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. robert.klein@mssm.edu.ORCID http://orcid.org/0000-0003-3539-5391

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Genetic Predictors of Prostate Cancer SurvivalR01CA244948 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ROBERT J. KLEIN · 2021 to 2026
$4.1M
Genomic and Transcriptomic Analysis of Mammographic DensityR01CA237541 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HABEL, LAUREL A, SIEH, WEIVA · 2020 to 2023
$2.0M
Cancerfonden (Swedish Cancer Society) 23 3074 Pj 01 HNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA237541NCI NIH HHS R01 CA244948
6 · The paper itself

Abstract

While prostate cancer (PrCa) is highly heritable, the genes associated with PrCa survival after diagnosis remain poorly understood. We aimed to identify genes associated with PrCa-specific survival through transcriptome-wide association studies (TWAS) using genetic predictors of gene expression in the prostate. We used the Transcriptome-Integrated Genetic Association Resource (TIGAR) to train expression prediction models separately using normal prostate, primary tumor, and metastatic tumor tissues. We performed TWAS using these models in data from the Malmö Diet and Cancer (MDC) study (discovery) and Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial (validation). We identified and validated seven genes associated with PrCa-specific survival at a common locus on chromosome 1. We found two genes using prediction models from normal prostate tissues and five with models from metastatic tumor tissues. Elevated RCC1 expression is linked to a shorter time to biochemical recurrence, while higher PHACTR4 expression was observed in tumors with a higher Gleason grade. The study is limited to European ancestry and can only show associations. Further research across other populations and experiments to establish causality will be needed. Our multi-tissue study identified novel genes associated with PrCa survival, particularly RCC1 and PHACTR4, providing new insights for potential genomic markers for PrCa survival.

Indexed as

Cell Cycle ProteinsGuanine Nucleotide Exchange FactorsNuclear ProteinsProstatic NeoplasmsTranscriptomeGene Expression Regulation, NeoplasticGenome-Wide Association StudyHumansMaleCell Cycle ProteinsGuanine Nucleotide Exchange FactorsNuclear Proteins

Identifiers

PMID42323493
PMCPMC13424128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.